Evolus, Inc. (NASDAQ:EOLS) Receives $21.25 Average Price Target from Analysts

Evolus, Inc. (NASDAQ:EOLS) has earned a consensus rating of “Hold” from the five research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $21.25.

A number of equities research analysts recently issued reports on EOLS shares. Wall Street Zen downgraded shares of Evolus from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Needham & Company LLC reissued a “hold” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a report on Saturday, September 27th. BTIG Research reiterated a “buy” rating and issued a $18.00 target price on shares of Evolus in a report on Monday, September 8th. Finally, HC Wainwright lowered their price target on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th.

Insider Transactions at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of Evolus stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $7.51, for a total transaction of $42,972.22. Following the transaction, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brady Stewart purchased 30,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average price of $6.82 per share, with a total value of $204,600.00. Following the completion of the acquisition, the director owned 88,629 shares in the company, valued at $604,449.78. This represents a 51.17% increase in their position. The disclosure for this purchase can be found here. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Evolus

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after buying an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after purchasing an additional 1,838 shares during the last quarter. Invesco Ltd. boosted its holdings in Evolus by 7.5% in the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after purchasing an additional 2,383 shares during the last quarter. Manchester Capital Management LLC acquired a new stake in Evolus during the 2nd quarter valued at approximately $26,000. Finally, AlphaQuest LLC purchased a new stake in Evolus during the 1st quarter worth approximately $39,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Price Performance

EOLS opened at $6.50 on Friday. Evolus has a 12 month low of $5.71 and a 12 month high of $17.82. The business has a 50-day moving average of $7.13 and a two-hundred day moving average of $9.13. The stock has a market capitalization of $420.42 million, a price-to-earnings ratio of -6.63 and a beta of 1.04.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.